EverGlade Insights Archives - EverGlade Consulting

EverGlade Insights

ARPA-H PROSPR prolonging resilience

EverGlade Consulting Funding Alert: PROactive Solutions for Prolonging Resilience (PROSPR)

Leave a Comment / ARPA-H, EverGlade Insights / By

ARPA-H-SOL-25-125_Special_Notice ARPA-H’s PROSPR Program The Advanced Research Projects Agency for Health (ARPA-H) has announced the PROactive Solutions for Prolonging Resilience (PROSPR) initiative, an ambitious program designed to extend the healthspan of Americans by addressing the underlying causes of age-related health loss. By pioneering innovative interventions that target age-induced health deterioration, ARPA-H aims to revolutionize healthcare […]

EverGlade Consulting Funding Alert: PROactive Solutions for Prolonging Resilience (PROSPR) Read More »

PAHPA program funding

The Continuing Resolution: Funding Opportunities and Unresolved Priorities

Leave a Comment / BARDA, EverGlade Insights / By

Congress is poised to pass a continuing resolution (CR), narrowly avoiding a shutdown and providing temporary relief. However, this short-term fix highlights critical gaps in public health and technology preparedness that demand immediate attention. As essential programs face expiration and threats beyond the Pandemic and All-Hazards Preparedness Act (PAHPA) remain unresolved, lawmakers must act swiftly

The Continuing Resolution: Funding Opportunities and Unresolved Priorities Read More »

Targeting Cancer Cells

EverGlade Consulting Helps SonALAsense Secure up to $46 Million in ARPA-H Funding

Leave a Comment / EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped SonALAsense successfully secure up to $46 million in funding to develop a minimally or non-invasive ultrasound treatment to activate a compound that can destroy cancer cells. Improving Patient Outcomes The $46 million in ARPA-H funding, announced as part of ARPA-H’s initiative to revolutionize cancer treatment through cutting-edge

EverGlade Consulting Helps SonALAsense Secure up to $46 Million in ARPA-H Funding Read More »

Radiation & Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices

Development of Radiation/Nuclear Medical Countermeasures And Biodosimetry Devices

Leave a Comment / EverGlade Insights, NIAID, Time Sensitive / By

NIAID_Presolicitation_Notice_Rad_Nuc MCMs Overview of Solicitation The National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), has released a pre-solicitation notice for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices. This Broad Agency Announcement (BAA 75N93024R00020) is an invitation for innovators in the critical field of radiation emergency

Development of Radiation/Nuclear Medical Countermeasures And Biodosimetry Devices Read More »

ACTR Initiative clinical trials

Transforming Clinical Trials with the Advancing Clinical Trial Readiness (ACTR) Initiative

Leave a Comment / ARPA-H, EverGlade Insights / By

ARPA-H launches groundbreaking funding opportunity The Advancing Clinical Trial Readiness (ACTR) Initiative, spearheaded by ARPA-H’s Resilient Systems Office (RSO), aims to revolutionize clinical trials by developing a decentralized, efficient, and accessible infrastructure. Overview of Solicitation The ACTR Initiative is focused on creating tools, networks, and infrastructure to enable decentralized and on-demand clinical trials. By integrating

Transforming Clinical Trials with the Advancing Clinical Trial Readiness (ACTR) Initiative Read More »

ARPA-H health equity, technology, and biomedical research

Emerging Health Innovators (EHI) Initiative Proposer’s Day

Leave a Comment / ARPA-H, EverGlade Insights / By

ARPA-H-SN-25-119 (1) The Advanced Research Projects Agency for Health (ARPA-H) has launched the Emerging Health Innovators (EHI) Initiative, a transformative funding opportunity aimed at empowering early-career researchers and community-based innovators to revolutionize healthcare. To support this initiative, ARPA-H is holding a virtual Proposer’s Day on January 8th, 2025, from 11AM to 4PM EDT. Overview of

Emerging Health Innovators (EHI) Initiative Proposer’s Day Read More »

medical countermeasures for biodefense and infectious diseases

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease

Leave a Comment / EverGlade Insights, NIAID, NIH / By

HHS-NIH-NIAID-BAA2025-1 The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has released the Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1. This announcement presents an exciting opportunity for researchers, organizations, and industry leaders to contribute to critical biomedical and biodefense initiatives.

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease Read More »

the Joint Biological Tactical Detection System

Joint Biological Tactical Detection System Full Rate Production Request for Information

Leave a Comment / EverGlade Insights, JPEO / By

JBTDS_FRP_RFI_4_Nov_2024_ The U.S. Army’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) recently issued a Request for Information (RFI) regarding Full Rate Production (FRP) of the Joint Biological Tactical Detection System (JBTDS). This RFI aims to collect information on industry capability to produce JBTDS devices which will be used by joint

Joint Biological Tactical Detection System Full Rate Production Request for Information Read More »

handheld diagnostic device

Assay Expansion for Chemical Diagnostic System

Leave a Comment / DTRA, EverGlade Insights / By

Assay-Expansion-for-Chemical-Diagnostics-System-SOO_Final The Defense Threat Reduction Agency’s Medical Diagnostics Branch (RD-CBMD) is driving innovation with its 2026 solicitation to expand the ChemDx platform. ChemDx is a handheld diagnostic device for rapid detection of chemical threats, such as nerve agents or certain pesticides, in blood from a finger prick. This effort seeks proposals from organizations interested in

Assay Expansion for Chemical Diagnostic System Read More »

drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

Leave a Comment / BARDA, EverGlade Insights / By

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

anti-microbial

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials

Leave a Comment / DPA, EverGlade Insights / By

HHS+DPA+T3+RFI_Antimicrobials+-+Clean+copy+11-7-24+(002) The U.S. Department of Health and Human Services (HHS) Defense Production Act (DPA) Title III Program recently issued a Request for Information (RFI) aimed at strengthening the domestic production of anti-microbial products. This initiative seeks input from industry to assess current capacities and capabilities in producing essential anti-microbials critical for public health and national

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials Read More »

antimicrobial-resistant (AMR) pathogens and viruses

NIAID Omnibus Broad Agency Announcement (BAA)

Leave a Comment / EverGlade Insights, NIAID, Time Sensitive / By

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through

NIAID Omnibus Broad Agency Announcement (BAA) Read More »

Scroll to Top
A yellow lab flask with Donald Trump hair and a red tie.

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.

Sign Up